TGDCA to Block Duplicate Medicine Brand Names to Prevent Patient Errors

The Telangana Drug Control Administration (TGDCA) in Hyderabad has been directed to enforce a strict "First-to-Register" rule to eliminate duplicate and deceptively similar medicine brand names. The directive, issued recently by the Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI), aims to prevent potentially fatal medication errors and stop pharmaceutical companies from using misleading brand extension strategies.

Under the new directive, state-level drug regulators must phase out duplicate naming conventions. Pharmaceutical companies often adopt a brand extension strategy, launching a drug with a name that resembles or rhymes with an established drug meant for a completely different disease. This marketing shortcut allows companies to ride on the reputation of existing drugs instead of building their own brand, which can lead to dangerous mix-ups for patients.

For instance, a patient could mistakenly take a potent hospital-grade sedative instead of a routine antacid because both drugs share the identical brand name "Medzol" but were manufactured in different states. To eliminate these risks, the "First-to-Register" policy dictates that the company that first submitted Form 51 under the Drugs Rules to the TGDCA will retain exclusive, absolute rights to that specific brand name.

The CDSCO and DCGI have directed the TGDCA to summarily withdraw the brand approvals of all subsequent manufacturers using the same name. This will force late-entering pharmaceutical majors to quickly recall, rename, and repackage their inventory. Companies that fail to comply face immediate criminal prosecution for marketing misbranded and spurious drugs under Section 17-B of the Drugs and Cosmetics Act.

Additionally, the TGDCA has been directed to utilize the Sugam portal to address the issue. Previously, when caught using duplicated names, pharmaceutical companies often claimed they did not know another company in India was already using a similar brand name.

Under the new regulations, all pharmaceutical manufacturers are legally mandated to upload their ingredient formulations along with their intended commercial brand names on the Sugam portal. When the TGDCA processes a new manufacturing application, the software will automatically cross-check the proposed name phonetically and visually against both the Sugam database and the national Trademark Registry. If the software flags a potential clash, the license for the duplicate brand name will be blocked at the entry point.